TG Therapeutics reported earnings of $ 0.35 per TGTX share on Nov 9, 2026, falling short of analysts' expectations by
| Report Date | Nov 9, 2026 |
|---|---|
| Forecasted EPS | $ 0.3593 |
| Earnings Per Share (Surprise) | $ 0.35 (-$ 0.01) |
| Last Year's EPS | $ 0.6925 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, TG Therapeutics beat analysts’ expectations 20 times and fell short of expectations 39 time(s). TG Therapeutics reported earnings per share of $ 0.35 in the last report falling to reach an estimated EPS of $ 0.3593 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 9, 2026 | $ 0.3593 | $ 0.35 | $ 2.43 | |
| Aug 3, 2026 | $ 0.3057 | $ 0.05 | $ 0.17 | |
| May 6, 2026 | $ 0.23 | $ 0.14 | $ 0.03 | |
| Feb 26, 2026 | $ 0.35 | $ 0.14 | $ 0.15 | |
| Nov 3, 2025 | $ 0.24 | $ 2.43 | $ 0.02 | |
| Aug 4, 2025 | $ 0.32 | $ 0.17 | $ 0.04 | |
| May 5, 2025 | $ 0.18 | $ 0.03 | -$ 0.07 | |
| Mar 3, 2025 | $ 0.08 | $ 0.15 | -$ 0.09 | |
| Nov 4, 2024 | $ 0.03 | $ 0.02 | $ 0.73 | |
| Aug 6, 2024 | -$ 0.05 | $ 0.04 | -$ 0.34 | |
| May 1, 2024 | -$ 0.04 | -$ 0.07 | -$ 0.28 | |
| Feb 28, 2024 | -$ 0.12 | -$ 0.09 | -$ 0.39 | |
| Nov 1, 2023 | $ 0.12 | $ 0.73 | -$ 0.26 | |
| Aug 1, 2023 | -$ 0.26 | -$ 0.34 | -$ 0.30 | |
| May 1, 2023 | -$ 0.36 | -$ 0.28 | -$ 0.51 | |
| Feb 28, 2023 | -$ 0.26 | -$ 0.39 | -$ 0.70 | |
| Nov 10, 2022 | -$ 0.33 | -$ 0.26 | -$ 0.65 | |
| Aug 8, 2022 | -$ 0.49 | -$ 0.30 | -$ 0.59 | |
| May 10, 2022 | -$ 0.55 | -$ 0.51 | -$ 0.69 | |
| Mar 1, 2022 | -$ 0.62 | -$ 0.70 | -$ 0.71 |
TG Therapeutics’s stock was trading at $ 59.83 on Nov 8, 2026 a day before the last earnings report was released.Following the release of the earnings report, TGTX’s price increased to $ 64.26 on Nov 10, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 9, 2026 | $ 0.35 | $ 59.83 | $ 64.26 | |
| Aug 3, 2026 | $ 0.05 | $ 52.03 | $ 48.74 | |
| May 6, 2026 | $ 0.14 | $ 36.10 | $ 43.03 | |
| Feb 26, 2026 | $ 0.14 | $ 29.66 | $ 30.09 | |
| Nov 3, 2025 | $ 2.43 | $ 34.78 | $ 33.81 | |
| Aug 4, 2025 | $ 0.17 | $ 35.02 | $ 28.40 | |
| May 5, 2025 | $ 0.03 | $ 43.44 | $ 34.86 | |
| Mar 3, 2025 | $ 0.15 | $ 30.09 | $ 35.62 | |
| Nov 4, 2024 | $ 0.02 | $ 26.90 | $ 25.86 | |
| Aug 6, 2024 | $ 0.04 | $ 17.21 | $ 19.99 | |
| May 1, 2024 | -$ 0.07 | $ 13.66 | $ 16.42 | |
| Feb 28, 2024 | -$ 0.09 | $ 13.91 | $ 17.22 | |
| Nov 1, 2023 | $ 0.73 | $ 7.73 | $ 10.41 | |
| Aug 1, 2023 | -$ 0.34 | $ 20.69 | $ 10.55 | |
| May 1, 2023 | -$ 0.28 | $ 24.83 | $ 31.16 | |
| Feb 28, 2023 | -$ 0.39 | $ 15.93 | $ 15.32 | |
| Nov 10, 2022 | -$ 0.26 | $ 5.16 | $ 9.34 | |
| Aug 8, 2022 | -$ 0.30 | $ 6.23 | $ 7.44 | |
| May 10, 2022 | -$ 0.51 | $ 6.41 | $ 5.71 | |
| Mar 1, 2022 | -$ 0.70 | $ 9.87 | $ 10.33 |
TG Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
TG Therapeutics missed analysts’ expectations during the last earnings period by
